Literature DB >> 32092639

Not all cancers are created equal: Tissue specificity in cancer genes and pathways.

Joy J Bianchi1, Xin Zhao1, Joseph C Mays1, Teresa Davoli2.   

Abstract

Tumors arise through waves of genetic alterations and clonal expansion that allow tumor cells to acquire cancer hallmarks, such as genome instability and immune evasion. Recent genomic analyses showed that the vast majority of cancer driver genes are mutated in a tissue-dependent manner, that is, are altered in some cancers but not others. Often the tumor type also affects the likelihood of therapy response. What is the origin of tissue specificity in cancer? Recent studies suggest that both cell-intrinsic and cell-extrinsic factors play a role. On one hand, cell type-specific wiring of the cell signaling network determines the outcome of cancer driver gene mutations. On the other hand, the tumor cells' exposure to tissue-specific microenvironments (e.g. immune cells) also contributes to shape the tissue specificity of driver genes and of therapy response. In the future, a more complete understanding of tissue specificity in cancer may inform methods to better predict and improve therapeutic outcomes.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Aneuploidy; Cancer driver genes; Cancer immune evasion; DNA damage response; Mutations; Tissue specificity

Mesh:

Year:  2020        PMID: 32092639      PMCID: PMC7247947          DOI: 10.1016/j.ceb.2020.01.005

Source DB:  PubMed          Journal:  Curr Opin Cell Biol        ISSN: 0955-0674            Impact factor:   8.382


  65 in total

1.  Tissue-specificity in cancer: The rule, not the exception.

Authors:  Kevin M Haigis; Karen Cichowski; Stephen J Elledge
Journal:  Science       Date:  2019-03-15       Impact factor: 47.728

2.  Estrogen controls the survival of BRCA1-deficient cells via a PI3K-NRF2-regulated pathway.

Authors:  Chiara Gorrini; Bevan P Gang; Christian Bassi; Andrew Wakeham; Shakiba Pegah Baniasadi; Zhenyue Hao; Wanda Y Li; David W Cescon; Yen-Ting Li; Sam Molyneux; Nadia Penrod; Mathieu Lupien; Edward E Schmidt; Vuk Stambolic; Mona L Gauthier; Tak W Mak
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-24       Impact factor: 11.205

3.  RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.

Authors:  Emma Nolan; François Vaillant; Daniel Branstetter; Bhupinder Pal; Göknur Giner; Lachlan Whitehead; Sheau W Lok; Gregory B Mann; Kathy Rohrbach; Li-Ya Huang; Rosalia Soriano; Gordon K Smyth; William C Dougall; Jane E Visvader; Geoffrey J Lindeman
Journal:  Nat Med       Date:  2016-06-20       Impact factor: 53.440

4.  Profound Tissue Specificity in Proliferation Control Underlies Cancer Drivers and Aneuploidy Patterns.

Authors:  Laura Magill Sack; Teresa Davoli; Mamie Z Li; Yuyang Li; Qikai Xu; Kamila Naxerova; Eric C Wooten; Ronald J Bernardi; Timothy D Martin; Ting Chen; Yumei Leng; Anthony C Liang; Kathleen A Scorsone; Thomas F Westbrook; Kwok-Kin Wong; Stephen J Elledge
Journal:  Cell       Date:  2018-03-22       Impact factor: 41.582

5.  Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy.

Authors:  Teresa Davoli; Hajime Uno; Eric C Wooten; Stephen J Elledge
Journal:  Science       Date:  2017-01-20       Impact factor: 47.728

Review 6.  Cancer immunotherapy using checkpoint blockade.

Authors:  Antoni Ribas; Jedd D Wolchok
Journal:  Science       Date:  2018-03-22       Impact factor: 47.728

7.  Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis.

Authors:  Takahiro Tsujikawa; Sushil Kumar; Rohan N Borkar; Vahid Azimi; Guillaume Thibault; Young Hwan Chang; Ariel Balter; Rie Kawashima; Gina Choe; David Sauer; Edward El Rassi; Daniel R Clayburgh; Molly F Kulesz-Martin; Eric R Lutz; Lei Zheng; Elizabeth M Jaffee; Patrick Leyshock; Adam A Margolin; Motomi Mori; Joe W Gray; Paul W Flint; Lisa M Coussens
Journal:  Cell Rep       Date:  2017-04-04       Impact factor: 9.423

8.  Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

Authors:  Peter Schmid; Sylvia Adams; Hope S Rugo; Andreas Schneeweiss; Carlos H Barrios; Hiroji Iwata; Véronique Diéras; Roberto Hegg; Seock-Ah Im; Gail Shaw Wright; Volkmar Henschel; Luciana Molinero; Stephen Y Chui; Roel Funke; Amreen Husain; Eric P Winer; Sherene Loi; Leisha A Emens
Journal:  N Engl J Med       Date:  2018-10-20       Impact factor: 91.245

9.  Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer.

Authors:  Sidharth V Puram; Itay Tirosh; Anuraag S Parikh; Anoop P Patel; Keren Yizhak; Shawn Gillespie; Christopher Rodman; Christina L Luo; Edmund A Mroz; Kevin S Emerick; Daniel G Deschler; Mark A Varvares; Ravi Mylvaganam; Orit Rozenblatt-Rosen; James W Rocco; William C Faquin; Derrick T Lin; Aviv Regev; Bradley E Bernstein
Journal:  Cell       Date:  2017-11-30       Impact factor: 41.582

10.  The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.

Authors:  Jill Hallin; Lars D Engstrom; Lauren Hargis; Andrew Calinisan; Ruth Aranda; David M Briere; Niranjan Sudhakar; Vickie Bowcut; Brian R Baer; Joshua A Ballard; Michael R Burkard; Jay B Fell; John P Fischer; Guy P Vigers; Yaohua Xue; Sole Gatto; Julio Fernandez-Banet; Adam Pavlicek; Karen Velastagui; Richard C Chao; Jeremy Barton; Mariaelena Pierobon; Elisa Baldelli; Emanuel F Patricoin; Douglas P Cassidy; Matthew A Marx; Igor I Rybkin; Melissa L Johnson; Sai-Hong Ignatius Ou; Piro Lito; Kyriakos P Papadopoulos; Pasi A Jänne; Peter Olson; James G Christensen
Journal:  Cancer Discov       Date:  2019-10-28       Impact factor: 38.272

View more
  9 in total

Review 1.  Mapping and Validation of scRNA-Seq-Derived Cell-Cell Communication Networks in the Tumor Microenvironment.

Authors:  Kate Bridges; Kathryn Miller-Jensen
Journal:  Front Immunol       Date:  2022-04-28       Impact factor: 8.786

2.  Immune evasion in HPV- head and neck precancer-cancer transition is driven by an aneuploid switch involving chromosome 9p loss.

Authors:  William N William; Xin Zhao; Joy J Bianchi; Heather Y Lin; Pan Cheng; J Jack Lee; Hannah Carter; Ludmil B Alexandrov; Jim P Abraham; David B Spetzler; Steven M Dubinett; Don W Cleveland; Webster Cavenee; Teresa Davoli; Scott M Lippman
Journal:  Proc Natl Acad Sci U S A       Date:  2021-05-11       Impact factor: 12.779

Review 3.  Text Mining for Building Biomedical Networks Using Cancer as a Case Study.

Authors:  Sofia I R Conceição; Francisco M Couto
Journal:  Biomolecules       Date:  2021-09-29

Review 4.  New Drug Development and Clinical Trial Design by Applying Genomic Information Management.

Authors:  Young Kyung Ko; Jeong-An Gim
Journal:  Pharmaceutics       Date:  2022-07-24       Impact factor: 6.525

5.  Analyzing cancer gene expression data through the lens of normal tissue-specificity.

Authors:  H Robert Frost
Journal:  PLoS Comput Biol       Date:  2021-06-18       Impact factor: 4.475

Review 6.  Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells.

Authors:  Abdulaziz B Hamid; Ruben C Petreaca
Journal:  Cancers (Basel)       Date:  2020-04-09       Impact factor: 6.639

Review 7.  Targeting DNA Damage Response in Prostate and Breast Cancer.

Authors:  Antje M Wengner; Arne Scholz; Bernard Haendler
Journal:  Int J Mol Sci       Date:  2020-11-04       Impact factor: 5.923

8.  5-Aryl-1-Arylideneamino-1H-Imidazole-2(3H)-Thiones: Synthesis and In Vitro Anticancer Evaluation.

Authors:  Ali H Abu Almaaty; Eslam E M Toson; El-Sherbiny H El-Sayed; Mohamed A M Tantawy; Eman Fayad; Ola A Abu Ali; Islam Zaki
Journal:  Molecules       Date:  2021-03-18       Impact factor: 4.411

9.  Copy-Number Alteration Burden Differentially Impacts Immune Profiles and Molecular Features of Hepatocellular Carcinoma.

Authors:  Laia Bassaganyas; Roser Pinyol; Roger Esteban-Fabró; Laura Torrens; Sara Torrecilla; Catherine E Willoughby; Sebastià Franch-Expósito; Maria Vila-Casadesús; Itziar Salaverria; Robert Montal; Vincenzo Mazzaferro; Jordi Camps; Daniela Sia; Josep M Llovet
Journal:  Clin Cancer Res       Date:  2020-09-01       Impact factor: 12.531

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.